Iovance BiotherapeuticsIOVA
IOVA
About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Employees: 838
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 34
19% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 84
6% more funds holding
Funds holding: 283 [Q3] → 299 (+16) [Q4]
1.98% more ownership
Funds ownership: 77.24% [Q3] → 79.22% (+1.98%) [Q4]
19% less capital invested
Capital invested by funds: $2.2B [Q3] → $1.79B (-$417M) [Q4]
21% less call options, than puts
Call options by funds: $28.9M | Put options by funds: $36.4M
22% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 7 (-2) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
39%
upside
Avg. target
$17.71
393%
upside
High target
$32
791%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Goldman Sachs Andrea Tan 44% 1-year accuracy 4 / 9 met price target | 346%upside $16 | Buy Maintained | 17 Apr 2025 |
Barclays Peter Lawson 14% 1-year accuracy 3 / 22 met price target | 39%upside $5 | Overweight Maintained | 14 Apr 2025 |
Truist Securities Asthika Goonewardene 30% 1-year accuracy 7 / 23 met price target | 318%upside $15 | Buy Maintained | 3 Mar 2025 |
Chardan Capital Geulah Livshits 10% 1-year accuracy 6 / 59 met price target | 736%upside $30 | Buy Maintained | 3 Mar 2025 |
Baird Michael Ulz 32% 1-year accuracy 6 / 19 met price target | 457%upside $20 | Outperform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 7 articles about IOVA published over the past 30 days
Positive
The Motley Fool
23 hours ago
2 Beaten-Down Stocks With Incredible Upside Potential
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
Neutral
GlobeNewsWire
1 week ago
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR Annual Meeting. In addition, five-year outcomes data from the C-144-01 study of lifileucel monotherapy in patients with advanced melanoma, and a poster on study design for lifileucel in frontline advanced non-small cell lung cancer, will be presented at the 2025 ASCO Annual Meeting.
Neutral
The Motley Fool
1 week ago
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
Iovance Biotherapeutics (IOVA 4.38%) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or metastatic melanoma.
Positive
The Motley Fool
1 week ago
This Biotech Stock Could Be the Best Investment of the Decade
Picking stocks with a relatively narrow timeframe in mind -- and with a particular performance expectation -- can be tricky. Most investors can distinguish between bad, good, and even-better investment prospects.
Neutral
GlobeNewsWire
1 week ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 297,600 shares of Iovance's common stock to fifty new, non-executive employees.
Neutral
The Motley Fool
2 weeks ago
Is Iovance Biotherapeutics a Millionaire-Maker?
Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money.
Positive
The Motley Fool
3 weeks ago
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Positive
The Motley Fool
1 month ago
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
Positive
The Motley Fool
1 month ago
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery.
Charts implemented using Lightweight Charts™